Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib
CAMBRIDGE, MA, USA I October 31, 2016 I ARIAD Pharmaceuticals, Inc.
UK Study Shows rifaximin-α (XIFAXAN® 550mg / TARGAXAN® 550mg) for Hepatic Encephalopathy May Reduce Costs to Healthcare Systems
Norgine B.
Astellas buys Ganymed to boost immuno-oncology pipeline
Astellas has agreed to pay €422m upfront to buy Ganymed Pharmaceuticals, a German biopharma company specialising in antibody-based cancer drugs.
Are hormonal contraceptives on the way for men?
Most birth control is designed to be used by women, with the exception of condoms and vasectomies.
Depression drugs sales in the US will reach $4.6 billion by 2025, says GlobalData
The US market for major depressive disorders (MDD) will rise from $2.
Seasonal influenza vaccines market will hit $4.3 billion by 2025, says GlobalData
The seasonal influenza vaccine market across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will rise from $3.
Eisai to initiate phase II clinical study of dual orexin receptor antagonist lemborexant in patients with irregular sleep-wake rhythm disorder and dementia
TOKYO, Japan I October 28, 2016 I Eisai Co.
AstraZeneca pauses two cancer drug trials' enrolment due to bleeding
AstraZeneca's high hopes for cancer immunotherapy were dented on Thursday as the recruitment of new patients with head and neck cancer into two clinical studies was put on hold, following instance...
Why BROCCOLI could reverse the signs of ageing: Compound in the vegetable 'slows down vision loss and middle-age spread'
Physical signs of ageing could be slowed down by a compound found in broccoli, cabbage and avocado, scientists claim.
Viriom Announces Appointment of New Scientific Advisory Board Member
SAN DIEGO, Oct.
LYNPARZA (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit
WILMINGTON, DE, USA I October 26, 2016 I AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZATM (olaparib) tablets (3...
Cefiderocol, A Novel Investigational Siderophore Cephalosporin, Demonstrated Potent Activity Against Multi-Drug Resistant Gram-Negative Pathogens
OSAKA, Japan and FLORHAM PARK, NJ, USA I October 26, 2016 I Shionogi & Co.
6
7
8
9
10
11
12
13
14
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds
